3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Breast Neoplasms
31
Neoplasms
8
Endometrial Neoplasms
6
Neoplasm Metastasis
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Meningioma
3
Glioblastoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Multiple Myeloma
1
Interventions
Cisplatin
28
Pemetrexed
22
Gemcitabine
10
Nivolumab
9
Carboplatin
9
pembrolizumab
8
tremelimumab
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Doxorubicin
4
Chemotherapy, Adjuvant
4
Vinorelbine
3
Ipilimumab
3
Bortezomib
3
Bevacizumab
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
sodium thiosulfate
2
sargramostim
2
niraparib
2
nintedanib
2
liposomal doxorubicin
2
lenvatinib
2
defactinib
2
cemiplimab
2
cediranib
2
amatuximab
2
Trabectedin
2
Neoadjuvant Therapy
2
Mitomycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma, Malignant
×
abemaciclib
×
Clear all
NCT03654833
2023-03-14
MiST
University of Leicester
Phase 2
Unknown
186 enrolled